Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a large growth in short interest in May. As of May 31st, there was short interest totalling 3,500 shares, a growth of 169.2% from the May 15th total of 1,300 shares. Based on an average daily volume of 4,500 shares, the short-interest ratio is currently 0.8 days. Currently, 0.0% of the company's stock are sold short.
Pharming Group Trading Down 6.0%
Shares of NASDAQ PHAR traded down $0.69 during mid-day trading on Friday, reaching $10.87. 3,787 shares of the company's stock were exchanged, compared to its average volume of 6,243. Pharming Group has a 52-week low of $6.65 and a 52-week high of $12.61. The company's 50-day moving average is $9.57 and its 200-day moving average is $9.13. The firm has a market capitalization of $739.57 million, a price-to-earnings ratio of -41.81 and a beta of 0.02. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. Analysts expect that Pharming Group will post -0.2 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer boosted their price objective on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research report on Friday, March 14th.
Check Out Our Latest Stock Analysis on PHAR
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
